MaxCyte

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MaxCyte reports robust Q4 earnings, poised for strategic growth

MaxCyte delivered impressive financial results in Q4 2022, showcasing strong revenue growth and a solid core business performance.
Despite facing challenges such as regulatory risks and industry dynamics, the company's strategic strengths and opportunities position it for continued success.
By maintaining a focus on innovation, partnership expansion, and financial prudence, MaxCyte aims to drive growth and navigate industry complexities effectively.

MaxCyte reports revenue decline but eyes growth through strategic partnerships

MaxCyte faced revenue declines in Q1 2023 due to industry challenges but remains positive about its future prospects and partnerships.
Despite financial setbacks, the company is focused on growth opportunities through new partnerships and potential product approvals.
Strategic guidance aims for revenue growth in 2023 and a healthy year-end cash position, signaling stability and long-term planning.

MaxCyte reports Q2 revenue decline but anticipates product approvals

MaxCyte faces revenue challenges but maintains confidence in its outlook with a strong partnership pipeline. The company's financials show a healthy gross margin and a focus on R&D for future growth. Anticipation surrounds the first commercial approval of products enabled by its platform.

MaxCyte meets Q3 revenue targets, eyes FDA milestone payments

MaxCyte's Q3 performance met expectations, with a focus on overcoming challenges in core business areas. The company's strengths lie in its optimism about non-viral engineered cell therapy trends and strong financial position.
While facing challenges in PA sales and operating expenses, MaxCyte sees opportunities in FDA approval milestones, revenue potential from SPL programs, and long-term growth through partnerships and industry support.

MaxCyte reports 2023 revenue decline but strong FDA approval growth

MaxCyte's 2023 performance saw revenue decline but significant achievements with FDA approval for CASGEVY and SPL client growth.
Despite challenges in core revenue, the company's strong financial position and robust SPL portfolio offer growth opportunities.
Guidance for 2024 indicates improved trends with flat to 5% growth, emphasizing the potential in SPL partnerships and financial stability.
Stabilization in funding and patient adoption present opportunities for revenue growth and market expansion in the cell therapy sector.

MaxCyte exceeds Q1 revenue expectations, poised for strategic growth

MaxCyte delivered strong Q1 2024 results, surpassing revenue expectations and demonstrating robust financial performance. With a focus on managing expenses and driving growth, the company is well-positioned to capitalize on its competitive strengths and market opportunities. Challenges lie in sustaining revenue growth and balancing expenses with expansion.

MaxCyte reports robust Q2 revenue, eyes cell therapy growth

MaxCyte's Q2 2024 performance showed solid revenue growth and a strong gross margin. The company's focus on cell therapy innovation and strategic partnerships positions it well for future growth.

MaxCyte exceeds revenue expectations, poised for sustainable growth

MaxCyte's Q3 2024 performance reflects robust revenue growth and strategic investments for long-term success.
While facing challenges like margin impact and cost management, the company's strengths in partnerships and leadership drive opportunities for expansion.
With increased revenue guidance and a disciplined spend approach, MaxCyte is poised for sustained growth and profitability.
Overall, MaxCyte's focus on core revenue, strategic partnerships, and leadership development sets a strong foundation for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MaxCyte's Flow Electroporation® technology and ExPERT™ platform will support Vittoria's Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies. MaxCyte's Flow Electroporation® technology and ExPERT™ platform will support Vittoria's Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies.

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

Lyell Immunopharma to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform in its T cell product candidates targeting solid tumors.

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

Cutting-edge cellular engineering firm MaxCyte (MXCT) has developed a platform which enables modifications to cells. Applications of MaxCyte's cellular engineering platform are far-reaching, such as cell-based therapies, gene editing, and drug discovery. With a $1.55+ billion backlog of milestones from Strategic Program Licenses and potential royalties longer term, MaxCyte is starting to look like an attractive investment.

MaxCyte: Engineering The Next Biotech Wave

MaxCyte, Inc. (NASDAQ:MXCT ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Sean Menarguez - Head-Investor Relations Doug Doerfler - President & Chief Executive Officer Douglas Swirsky - Chief Financial Office Conference Call Participants Julie Simmonds - Panmure Gordon Dan Arias - Stifel Hannah Hefley - Stephens Steven Mah - TD Cowen Madeline Mollman - William Blair Vidyun Bais - BTIG Operator Good day, and thank you for standing by and welcome to MaxCyte's First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

MaxCyte, Inc. (MXCT) Q1 2023 Earnings Call Transcript

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates

ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, today announced financial results for the first quarter ended March 31, 2023, and updated 2023 revenue guidance.

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

Walking Fish to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases Walking Fish to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

ProPhase Labs

Zomedica

CorMedix

Matinas BioPharma Hlds

Ocuphire Pharma

Sensus Healthcare

While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded.

7 Small-Cap Biotech Stocks with Massive Potential

ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced that it will release financial results for the first quarter 2023 after the U.S. market close on Wednesday, May 10th, 2023. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

MaxCyte's flow electroporation technology has made them the industry leader and the best bet for biotech companies that need a partner that specializes in non-viral cell engineering. MaxCyte's revenue mostly comes from milestone and royalty payments for licenses and SPLs who are looking to use their technology to develop and commercialize cutting-edge therapies.

MaxCyte: Picking Up This Pick And Shovel Play For Next-Gen Therapies

ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations.

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

MaxCyte, Inc. (NASDAQ:MXCT ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Sean Menarguez - Investor Relations Doug Doerfler - President and Chief Executive Officer Ron Holtz - Interim Chief Financial Officer Conference Call Participants Julie Simmonds - Panmure Gordon Dan Arias - Stifel Matt Larew - William Blair Jacob Johnson - Stephens Vidyun Bais - BTIG Operator Good day and thank you for standing by and welcome to MaxCyte's Fourth Quarter Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

MaxCyte, Inc. (MXCT) Q4 2022 Earnings Call Transcript

31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue 31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue

MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results

MaxCyte's Scientific Advisory Board will provide guidance to shape the technical direction of the company's innovation initiatives focused on the discovery, development and manufacturing of next-generation, cell-based medicines MaxCyte's Scientific Advisory Board will provide guidance to shape the technical direction of the company's innovation initiatives focused on the discovery, development and manufacturing of next-generation, cell-based medicines

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

ROCKVILLE, Md., March 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced preliminary revenue results for the fourth quarter and full year 2022 and provided initial 2023 revenue guidance.

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance

B2Gold

Denison Mines

Ferroglobe

Planet Labs

RLX Technology

Silvercorp Metals

For anyone interested in must-buy penny stocks to add to your portfolio in 2023, the framework comes down to a single concept: high risk, and high rewards. To be sure, anyone venturing into this space must acknowledge that the sector represents a gamble.

7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023

ROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15th, 2023. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences

MaxCyte's Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell therapies MaxCyte's Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell therapies

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

MaxCyte, Inc. (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Agenus

Apollo Global Management

Novo Nordisk

Trip.com

Tuniu Corp

Willis Lease Finance

Although a new year tends to bring feelings of optimism, when it comes to the current market dynamics, it's time to consider hot stocks to book profits in before 2023 arrives. At first, circumstances appeared favorable, with CNN reporting on Dec. 13 that inflation cooled more than expected.

7 Hot Stocks to Book Profits In Before 2023

MaxCyte, Inc. (MXCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade

Overall bearish sentiment has increased the likelihood of finding bargains in healthcare stocks. MaxCyte, Inc.'s prospects are bright while the price currently looks attractive relative to the growth potential.

MaxCyte Is Poised For A Strong Rebound

MaxCyte Inc (AIM:MXCT) has signed a strategic platform licence with a South Korean biotechnology company to enable cell and gene therapies for the treatment of rare intractable diseases. The cell engineering company said it will receive platform licensing fees and program-related revenue as part of the agreement.

MaxCyte signs strategic platform licence with South Korean biotech

Curamys to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology. Curamys to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology.

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

MaxCyte, Inc. (NASDAQ:MXCT ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Sean Menarguez - Director of Investor Relations Douglas Doerfler - Founder, President & Chief Executive Officer Ronald Holtz - Interim Chief Financial Officer Conference Call Participants Julie Simmonds - Panmure Gordon Madeline Mollman - William Blair Daniel Arias - Stifel Max Masucci - Cowen and Company Hannah Hefley - Stephens Inc. Vidyun Bais - BTIG Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the MaxCyte Third Quarter Earnings Conference Call.

News for MaxCyte Stock (MXCT)